Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
复制标题
DOI：
10.3390/cancers11101611
复制
发表时间：
2019-10-01
期刊：
影响因子：
5.2
通讯作者：
Jacobs, Julie
中科院分区：
文献类型：
--
作者：
Flieswasser, Tal;Camara-Clayette, Valerie;Jacobs, Julie
CD70 的组成型表达已在各种血液学和实体瘤类型中得到描述。此外，已证明其受体在肿瘤中共表达，介导肿瘤细胞增殖。尽管CD70表达是招募患者参加使用抗CD70免疫疗法的实体瘤临床试验的先决条件，但目前没有评估CD70表达的标准化测试。免疫组织化学 (IHC) 方案的这些差异使得比较不同研究中获得的表达水平具有挑战性，这表明需要一种统一的方法。在这项回顾性研究中，使用一种经过验证的 IHC 方法对来自不同实体和血液恶性肿瘤的 600 多个肿瘤样本进行了分析。 CD70 和 CD27 表达在多种肿瘤类型中得到证实。在实体瘤中，43% 的人表现出 CD70 阳性，其中肾细胞癌的阳性程度最高 (79.5%)。卡波西肉瘤的肿瘤细胞上不表达 CD70。在淋巴瘤样本中，58% 表现出 CD70 阳性。此外，在 39% 的淋巴瘤样本中观察到 CD70 和 CD27 共表达。这些发现强调需要在广泛的表达 CD70 的肿瘤类型中进一步探索抗 CD70 疗法，并在此过程中实施一种标准化方案来定义 CD70 过度表达，以将其用作诊断工具。
The constitutive expression of CD70 has been described in various haematological and solid tumour types. In addition, the co-expression of its receptor in tumours has been demonstrated, mediating tumour cell proliferation. Although CD70 expression is a prerequisite to enrol patients in solid tumour clinical trials using anti-CD70 immunotherapy, there is currently no standardised test to evaluate CD70 expression. These differences in immunohistochemistry (IHC) protocols make it challenging to compare the expression levels that were obtained in different studies, pointing out the need for one uniform methodology. In this retrospective study, over 600 tumour samples from different solid and haematological malignancies were analysed while using one validated IHC method. CD70 and CD27 expression was demonstrated in a broad range of tumour types. In solid tumours, 43% demonstrated CD70 positivity with the highest degree in renal cell carcinoma (79.5%). Kaposi sarcoma showed no CD70 expression on the tumour cells. In lymphoma samples, 58% demonstrated CD70 positivity. Moreover, the co-expression of CD70 and CD27 was observed in 39% of lymphoma samples. These findings highlight the need to further explore anti-CD70 therapies in a broad range of CD70 expressing tumour types and in doing so, implementing one standardised protocol to define CD70 overexpression to use it as a diagnostic tool.